# To Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy (0476-366)

> **NCT00398151** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 58 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** MK0476, montelukast sodium / Duration of Treatment: 12 Weeks

## Key facts

- **NCT ID:** NCT00398151
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-08-01
- **Primary completion:** 2006-01-18
- **Final completion:** 2006-01-18
- **Target enrollment:** 58 (ACTUAL)
- **Last updated:** 2024-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00398151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00398151, "To Evaluate the Inflammatory Markers in Adult Patients With Asthma Associated With Allergic Rhinitis Receiving Montelukast Therapy (0476-366)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00398151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*